Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147M
-
Number of holders
-
66
-
Total 13F shares, excl. options
-
62.2M
-
Shares change
-
+1.39M
-
Total reported value, excl. options
-
$949M
-
Value change
-
+$18.8M
-
Number of buys
-
46
-
Number of sells
-
-18
-
Price
-
$15.25
Significant Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q2 2018
74 filings reported holding DNLI - Denali Therapeutics Inc. - COMMON STOCK as of Q2 2018.
Denali Therapeutics Inc. - COMMON STOCK (DNLI) has 66 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 62.2M shares
of 147M outstanding shares and own 42.27% of the company stock.
Largest 10 shareholders include Crestline Management, LP (20.6M shares), Flagship Pioneering Inc. (8.92M shares), FMR LLC (8.04M shares), BAILLIE GIFFORD & CO (5.34M shares), FIL Ltd (4.54M shares), Temasek Holdings (Private) Ltd (4.41M shares), VANGUARD GROUP INC (3.17M shares), BlackRock Inc. (1.12M shares), BAMCO INC /NY/ (945K shares), and Alphabet Inc. (536K shares).
This table shows the top 66 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.